首页> 外文期刊>Systematic Reviews >Sensitivity and specificity of using trial-of-antibiotics versus sputum mycobacteriology for diagnosis of tuberculosis: protocol for a systematic literature review
【24h】

Sensitivity and specificity of using trial-of-antibiotics versus sputum mycobacteriology for diagnosis of tuberculosis: protocol for a systematic literature review

机译:使用抗生素试验与痰分枝杆菌学进行结核病诊断的敏感性和特异性:系统文献综述的方案

获取原文
           

摘要

Suboptimal diagnostics for pulmonary tuberculosis (PTB) drives use of ‘trial-of-antibiotics (non-tuberculosis)’ in an attempt to distinguish PTB patients from those with bacterial lower respiratory tract infection (LRTI). The underlying assumption—that patients with LRTI will report ‘response’ to broad-spectrum antibiotics, while those with PTB will not—has minimal evidence base for such a widely used intervention. Numerous potential causes of misclassification include bacterial super-infection of active PTB, placebo effect, and antimicrobial resistance (AMR). The main aim of this systematic review is to collate available evidence on the performance of trial-of-antibiotics as a diagnostic test and to explore the timing, interpretation, and decision-making process. We will search MEDLINE, Embase, and Global Health using the Ovid platform for published studies that recruited adults being investigated for PTB, performed trial-of-antibiotics accompanied by mycobacteriological investigations, and reported both diagnostic test outcomes at the individual level. Following article selection, two authors will independently review titles and abstracts against eligibility criteria then perform full-text screening and extraction into a spreadsheet. We will conduct a risk of bias assessment at the level of the study using QUADAS-2 (University of Bristol) tool that assesses diagnostic evaluation work in four domains: (1) patient selection, (2) the index test, (3) the reference standard, and (4) patient flow and timing of tests. We will perform a narrative synthesis and, where possible, meta-analyses addressing our primary outcome. Our protocol adheres to the standards recommended by the PRISMA-P. Pooling all available evidence on the accuracy, approach, and interpretation of results of trial-of-antibiotics in the context of PTB diagnosis will meet an urgent need, considering the widespread utilisation and potential for antimicrobial resistance. We therefore believe that our findings will have impact on policy and that they will inform the design of future detailed investigations into this important diagnostic approach.
机译:肺结核(PTB)的次优诊断促使人们使用“抗生素试验(非结核病)”,以试图将PTB患者与细菌性下呼吸道感染(LRTI)患者区分开。基本假设(LRTI患者将报告对广谱抗生素有“反应”,而PTB患者则不会)对这种广泛使用的干预措施的证据很少。错误分类的许多潜在原因包括细菌对活性PTB的过度感染,安慰剂作用和抗药性(AMR)。这项系统评价的主要目的是整理有关抗生素试验作为诊断测试的性能的现有证据,并探讨时机,解释和决策过程。我们将使用Ovid平台搜索MEDLINE,Embase和Global Health,以进行已发布的研究,这些研究招募正在接受PTB检查的成年人,进行了抗生素试验以及分枝杆菌调查,并在个人水平上报告了两种诊断测试的结果。选择文章后,两位作者将根据资格标准独立审查标题和摘要,然后执行全文筛选并将其提取到电子表格中。我们将使用QUADAS-2(布里斯托大学)工具在研究水平上进行偏倚评估风险,该工具可评估四个领域的诊断评估工作:(1)患者选择,(2)指标测试,(3)参考标准,以及(4)患者流量和测试时间。我们将进行叙述性综合,并在可能的情况下进行针对我们主要结果的荟萃分析。我们的协议符合PRISMA-P建议的标准。考虑到抗菌药物耐药性的广泛利用和潜力,在PTB诊断的背景下汇集有关抗生素试验结果的准确性,方法和解释的所有现有证据将满足迫切需要。因此,我们认为我们的发现将对政策产生影响,并将为将来对该重要诊断方法的详细调查提供信息。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号